EYPT
EyePoint Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.58
+0.33%Aug 28, 2026, 23:10 UTC
Kessler Topaz Meltzer & Check LLP launched an investigation into EyePoint, Inc. for potential federal securities law violations on behalf of investors who suffered significant losses.
Source:Aug 14, 2026, 20:32 UTC
EyePoint, Inc. granted non-statutory stock options to new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4).
Source:Aug 5, 2026, 11:00 UTC
EyePoint, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting $180 million in cash and investments as of that date.
Source: